Skip to main content
. Author manuscript; available in PMC: 2013 Aug 9.
Published in final edited form as: Virology. 2008 Sep 18;380(2):285–295. doi: 10.1016/j.virol.2008.07.007

Fig. 2.

Fig. 2

Neutralization by GP vaccine sera. (A) The effect of sCD4 on neutralization by GP sera 82-2 and 82-4. Pre-immune and vaccine sera are shown by open and filled symbols respectively. The IC50 and IC80 of sCD4 against each virus are indicated on the X-axis. (B) Serial dilutions of GP vaccine sera alone, or with a fixed concentration of sCD4 were tested to calculate the impact of sCD4 on the potency of serum neutralization. (C) With 5 ug/ml of sCD4 present, GP vaccine sera neutralize JRFL predominantly via anti-V3 antibodies. A V3 peptide (30 ug/ml) matched to the vaccine immunogen was used to inhibit the V3 mediated neutralization by GP vaccine sera. A scrambled V3 peptide had no inhibitory effect (not shown).